Skip to main content
SpringerLink
Log in

Hypertension in the elderly

  • Nifedipine in Hypertension
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Cardiovascular disease in all its clinical manifestations progresses significantly as age advances and takes its heaviest toll in the elderly. Hypertension becomes the dominant risk factor for cardiovascular disease in this age group because of its high incidence. Traditionally, diastolic rather than systolic blood pressure has been regarded as the main risk factor for cardiovascular complications in hypertension, although it is becoming clearer that the risk of cardiovascular complications is likely to be associated mainly with systolic pressure in the elderly.

Various intervention drug trials in elderly patients seem to indicate that hypotensive drug treatment can decrease cardiovascular mortality, mainly by decreasing cerebrovascular mortality. The EWPHE used a diuretic combination with methyldopa, and the HEP study used atenolol with a thiazide diuretic. The multicenter Systolic Hypertension in the Elderly Program (SHEPS) currently underway in the United States is likely to also provide some answers. The place of newer agents such as ACE inhibitors or calcium antagonists is still undetermined. Calcium antagonist drugs have been reported to be effective, and possibly more so in the elderly than in a younger population, although this assumption is not proven and may not be valid. Pharmacokinetic studies in the elderly are very few, although the studies reported indicate a reduced clearance. Studies also indicate that Nifedipine Retard tablets are effective, with a low incidence of adverse effects. There are no trials, however, looking at the long-term benefit of treating elderly hypertensive patients with either nifedipine tablets or other calcium-channel blockers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kannel WB, Gordon T. Evaluation of cardiovascular risk in the elderly: The Framingham Study.Bull NY Acad Med 1978;54:573–591.

    CAS  Google Scholar 

  2. Kannel WB, Vokonas PS. Cardiovascular risk factors in the elderly: The Framingham Study. In: Maddox GL, Bussi EW, eds.Aging: The universal human experience. New York: Springer, 1987:134–152.

    Google Scholar 

  3. Kannel WB. Prevalence, incidence and hazards of hypertension in the elderly.Am Heart J 1986;112:1362–1363.

    Article  PubMed  CAS  Google Scholar 

  4. Gordon T, Shiertleff D., Section 29. Means at each examination and enter examination variations of specific characteristics: Framingham Study. Exam 1 to Exam 10. In: Kannel WB, Gordon T, eds.The Framingham Study: An epidemiological investigation of cardiovascular disease. Washington DC: DHEW National Institutes of Health, 1977:474–478.

    Google Scholar 

  5. Kannel WB, Brand FN. Cardiovascular risk factors in the elderly. In: Andres R, Biermann EG, Hazzard WR, eds.Principles of Geriatric Medicine. New York: McGraw-Hill, 1985:104–119.

    Google Scholar 

  6. Amery A, Brixko R, Clermont D, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial.Lancet 1985;1:1349–1354.

    Article  PubMed  CAS  Google Scholar 

  7. Cooke J, Warrender TS. Randomized trial of treatment of hypertension in elderly patients in primary care.Br Med J 1986;293:1145–1151.

    Google Scholar 

  8. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressures averaging 90 through 114 mm Hg.JAMA 1970; 213:1143–1152.

    Google Scholar 

  9. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562–2571.

    Google Scholar 

  10. Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Treatment of mild hypertension in the elderly.Med J Aust 1981;2:398–402.

    Google Scholar 

  11. Staessen J, Fagard R, Van Hoof R, Amery A. Mortality in various intervention trials in elderly hypertensive patients.Eur Heart J 1988;9:215–222.

    PubMed  CAS  Google Scholar 

  12. Kuramoto K, Matsuhiti S, Kuwajima I, Murakawi M. Prospective study in the treatment of mild hypertension in the aged.Jpn Heart J 1981;22:75–85.

    PubMed  CAS  Google Scholar 

  13. Sprackling ME, Mitchell JRA, Short AH, Watt G. Blood pressure reduction in the elderly: A randomized controlled trial of methyldopa.Br Med J 1981;283:1151–1153.

    CAS  Google Scholar 

  14. Cruikshank JM, Pennert K, Sorman AE. Low mortality from all causes, including myocardial infarction in well controlled hypertensives treated with a beta-blocker plus other hypertensives.J Hypertens 1987;5:489–498.

    PubMed  Google Scholar 

  15. Cruikshank JM, Thorp JM, Zacharras FJ. Benefits and potential harm of lowering blood pressure.Lancet 1987;1:581–584.

    Article  PubMed  Google Scholar 

  16. Staessen J, Bulpitt C, Clement D, et al. Relation between mortality and treatment blood pressure in elderly patients with hypertension: Report of the European Working Party on high blood pressure in the elderly.Br Med J 1989; 298:1552–1556.

    Article  CAS  Google Scholar 

  17. Chalmers JP, Smith SA, Wing LMH. Hypertension in the elderly: The role of calcium antagonists.J. Cardiol Pharmacol 1988;12(Suppl 8):S147-S155.

    Google Scholar 

  18. Stessman J, Lerbel B, Yagel Y, et al. Nifedipine in the treatment of hypertension in the elderly.J Clin Pharmacol 1985;25:193–196.

    PubMed  CAS  Google Scholar 

  19. Landmark K, Dale J. Antihypertensive, hemodynamic and metabolic effects of nifedipine slow-release tablets in elderly patients.Acta Med Scand 1985;218:389–396.

    Article  PubMed  CAS  Google Scholar 

  20. Schnapp P, Herman H, Cernak P, Kabay J. Nifedipine monotherapy in the hypertension elderly: A placebo controlled medical trial.Curr Med Res Opin 1987;10:407–413.

    PubMed  CAS  Google Scholar 

  21. MacDonald G, St. Léger PB. Lack of relationship between age and the antihypertensive effect of nifedipine tablets in patients up to 70 years of age.Br J Clin Pract 1987;41:659–662.

    PubMed  CAS  Google Scholar 

  22. Garnier-Moiroux A, Henry JF, Taburet AM, et al. Pharmacocinétique de la nifédipine en comprimé chez le sujet âgé.Thérapie 1987;42:511–514.

    PubMed  CAS  Google Scholar 

  23. Erne P, Bolli P, Bertel O, et al. Factors influencing the hypotensive effects of calcium antagonists.Hypertension 1983;5(Suppl 11):97–102.

    Google Scholar 

  24. Muller FB, Bolli P, Erne P, et al. Antihypertensive therapy with the long-acting calcium antagonist nitrendipine.J Cardiol Pharmacol 1984;6:S1073-S1074.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut de Recherches Cliniques de Montréal, Hôtel-Dieu de Montréal, Montréal, Canada

    Pierre Larochelle MD, PhD, FRCPC

  2. Département de Pharmacologie, Université de Montréal, Montréal, Canada

    Pierre Larochelle MD, PhD, FRCPC

Authors
  1. Pierre Larochelle MD, PhD, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Larochelle, P. Hypertension in the elderly. Cardiovasc Drug Ther 4 (Suppl 5), 947–950 (1990). https://doi.org/10.1007/BF02018298

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02018298

Key Words

Search

Navigation